U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Russia Strikes Kharkiv and Izmail as Cross-Border Drone War Escalates
Israel Eyes Litani River as New Border Amid Escalating Lebanon Offensive
Jay Bhattacharya to Continue Leading CDC as White House Searches for Permanent Director
FEMA Reinstates $1 Billion Disaster Prevention Grant Program After Court Order
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Russia-Iran Military Alliance Deepens With Drone Shipments Amid Middle East Tensions
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Cuba Receives Humanitarian Aid Convoy Amid U.S. Sanctions
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Pakistan's Diplomatic Rise: Mediating U.S.-Iran Peace Talks
Trump Backs Down on Iran Strikes After Gulf Allies Sound the Alarm
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 



